Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma

Biochemical and Biophysical Research Communications

Volumn 403, Issue 3-4, 2010, Pages 417-421

  Zhao, Xiaohai ^a   Li, Jinfeng ^a   Zhuo, Jianxin ^a   Cai, Liuxin ^b  

^a Yueqing Second People's Hospital of Zhejiang   (China)

^b TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Angiogenesis; Aplasia Ras homolog member I (ARHI); Growth; Hepatocellular carcinoma (HCC); Mammalian target of rapamycin (mTOR)

Indexed keywords

APLASIA RAS HOMOLOG MEMBER I; CD31 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1 ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; RECOMBINANT PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HEP3B; CELL STRAIN SK HEP1; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; ENZYME SUBSTRATE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT;

ANGIOGENIC PROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RHO GTP-BINDING PROTEINS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA;

EID: 78650175085     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.046     Document Type: Article

References (39)

1. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
2. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
3. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
4. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10:25-34.
5. Poon R.T.P., Ng I.O., Lau C., et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J. Clin. Oncol. 2002, 20:1775-1785.
6. Sugimachi K., Tanaka S., Terashi T., Taguchi K., Rikimaru T., Sugimachi K. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 2002, 131:S135-S141.
7. Sugino T., Yamaguchi T., Hoshi N., et al. Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis. Clin. Exp. Metastasis 2008, 25:835-841.
8. El-Assal O.N., Yamanoi A., Soda Y., et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998, 27:1554-1562.
9. Ng I.O., Poon R.T., Lee J.M., Fan S.T., Ng M., Tso W.K. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol. 2001, 116:838-845.
10. von Marschall Z., Cramer T., Höcker M., Finkenzeller G., Wiedenmann B., Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001, 48:87-96.
11. Yu Y., Xu F., Peng H., et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. USA 1999, 96:214-219.
12. Wan X., Shen N., Mendoza A., Khanna C., Helman L.J. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006, 8:394-401.
13. Stephan S., Datta K., Wang E., et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin. Cancer Res. 2004, 10:6993-7000.
14. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., Kaelin W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003, 4:147-158.
15. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8:128-135.
16. Inoki K., Corradetti M.N., Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 2005, 37:19-24.
17. Luo R.Z., Fang X., Marquez R., et al. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003, 22:2897-2909.
18. Yu Y., Fujii S., Yuan J., et al. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann. N. Y. Acad. Sci. 2003, 983:268-277.
19. Rosen D.G., Wang L., Jain A.N., et al. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin. Cancer Res. 2004, 10:6559-6566.
20. Wang L., Hoque A., Luo R.Z., et al. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin. Cancer Res. 2003, 9:3660-3666.
21. Nishimoto A., Yu Y., Lu Z., et al. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res. 2005, 65:6701-6710.
22. Lu Z., Luo R.Z., Lu Y., et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest. 2008, 118:3917-3929.
23. Huang J., Lin Y., Li L., et al. ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis. Mol. Carcinog. 2009, 48:130-140.
24. Weber F., Aldred M.A., Morrison C.D., et al. Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J. Clin. Endocrinol. Metab. 2005, 90:1149-1155.
25. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 2005, 23:7212-7220.
26. Shih S.C., Robinson G.S., Perruzzi C.A., et al. Molecular profiling of angiogenesis markers. Am. J. Pathol. 2002, 161:35-41.
27. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 2007, 16:R50-R59.
28. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
29. Folkman J. Angiogenesis-dependent diseases. Semin. Oncol. 2001, 28:536-542.
30. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23:1011-1027.
31. Poon R.T.P., Ho J.W., Tong C.S., Lau C., Ng I.O., Fan S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 2004, 91:1354-1360.
32. Liu L., Cao Y., Chen C., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66:11851-11858.
33. Scagliotti G., Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist 2010, 15:436-446.
34. Kaseb A.O., Hanbali A., Cotant M., Hassan M.M., Wollner I., Philip P.A. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009, 115:4895-4906.
35. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
36. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
37. Land S.C., Tee A.R. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem. 2007, 282:20534-20543.
38. Huynh H., Chow K.H., Soo K.C., et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J. Cell. Mol. Med. 2009, 13:1371-1380.
39. Semela D., Piguet A.C., Kolev M., et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol. 2007, 46:840-848.